Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Roche Holding AG's Enterprise Value is CHF286,728 Mil.
Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF18,319 Mil. Therefore, Roche Holding AG's EV-to-EBIT ratio for today is 15.65.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Roche Holding AG's Enterprise Value is CHF286,728 Mil.
Roche Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF21,705 Mil. Therefore, Roche Holding AG's EV-to-EBITDA ratio for today is 13.21.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Roche Holding AG's Enterprise Value is CHF286,728 Mil.
Roche Holding AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF63,356 Mil. Therefore, Roche Holding AG's EV-to-Revenue ratio for today is 4.53.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Roche Holding AG's Enterprise Value is CHF286,728 Mil.
Roche Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13,073 Mil. Therefore, Roche Holding AG's EV-to-FCF ratio for today is 21.93.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Roche Holding AG (XSWX:ROP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Roche Holding AG's current Enterprise Value is CHF286,728 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF18,319 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Roche Holding AG's current Enterprise Value is CHF286,728 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF21,705 Mil.
Roche Holding AG's current Enterprise Value is CHF286,728 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF63,356 Mil.
Roche Holding AG's current Enterprise Value is CHF286,728 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF18,852 Mil.
Roche Holding AG's current Enterprise Value is CHF286,728 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13,073 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG Enterprise Value Related Terms
Roche Holding AG Enterprise Value Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ROP vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Roche Holding AG's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of CHF286,728 Mil mean?
Roche Holding AG (XSWX:ROP) has a Enterprise Value of CHF286,728 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Enterprise Value too high?
Roche Holding AG's current Enterprise Value is CHF286,728 Mil. Overall, Roche Holding AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Enterprise Value compare to LLY and JNJ?
Roche Holding AG's Enterprise Value of CHF286,728 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Enterprise Value is CHF286,728 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current Enterprise Value is CHF286,728 Mil. Roche Holding AG's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current Enterprise Value is CHF286,728 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
Enterprise Value: CHF286,728 Mil
GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
80GF Score
Get the complete analysis for XSWX:ROP
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 
